4M Therapeutics Inc.

At 4M Therapeutics we develop therapies for central nervous system (CNS) disorders, applying unique insights from our living human brain cell platform.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Montgomery Township, NJ, USA
  • Currency USD
  • Founded January 2021
  • Employees 3
  • Incorporation Type C-corp
  • Website 4mtx.net

Company Summary

4MTx is a neuroscience biotech startup. Our platform of technology from Harvard, MIT, and U. Washington uses human brain cells in drug discovery.

We focus on targets for a wide array of disorders such as Alzheimer's disease and bipolar disorder for which our small molecule 4MT2001 shows efficacy like lithium in animals while promising much better safety. We are on track for a Phase 1 study in early 2025.

Team

  • Chief Executive Officer

    Pablo has over 25 years of experience in biotech, including 12 years as Chief Medical Officer, experience in neuroscience, and a record of drug approvals. He was previously CMO at Lexicon Pharmaceuticals, VP of Clinical Development at Bristol-Myers Squibb, and CMO at Cogentus Pharmaceuticals. He has published in both the New England Journal of Medicine and the Wall Street Journal. His MD and BA are from Harvard University.

  • VP of Corporate Development and Co-founder

    Ben was CEO/Co-founder of Firecracker, an adaptive learning healthcare platform acquired by Wolters Kluwer (Euronext: WKL). He was also CEO/Founder of Firefly Health, an online support community for patients with 40,000+ members. He was also Executive Director of the Foundation for International Medical Relief of Children (FIMRC), a nonprofit providing health care to millions of children worldwide. His B.A. is from Harvard College.

  • Stephen Haggarty
    Scientific Founder

    Associate Professor of Neurology at Harvard Medical School, Associate Neuroscientist at Massachusetts General Hospital, and Director of the MGH Chemical Neurobiology Laboratory. Dr. Haggarty is also a Senior Associate Member of the Broad Institute of Harvard & MIT and Affiliate Faculty Member of the Harvard Stem Cell Institute. His research has identified the mechanism of action of lithium in treating bipolar disorder.

  • Li-Huei Tsai
    Scientific Founder

    Director, the Picower Institute for Learning and Memory at MIT. Picower Professor of Neuroscience, department of Brain and Cognitive Sciences. Senior Associate member, Broad Institute. Dr. Tsai is a leader in the study of biological pathways involved in Alzheimer's disease and other neurological disorders.

  • Scientific Founder

    Randy is a world leader in regenerative medicine. He is Professor emeritus at the University of Washington where he founded the institute for Stem Cell research and Regenerative Medicine. He has hundreds of publications and is a member of both the American Academy of Arts & Sciences and the National Academy of Sciences. He was senior scientific cofounder of Fate Therapeutics, which has made important progress in the treatment of cancer.

  • Alan Barber
    Chief Financial Officer

    Alan is Founder and Principal of the Prestar Group and has >30 years of life sciences experience. He has served as CFO and advisor to numerous companies including Karyopharm Therapeutics, Forma Therapeutics, Foundation Medicine, Marinus Pharmaceuticals, Durata Therapeutics and Repligen. He has assisted in raising more than $500 million in development and growth capital in the private and public financial markets (including IPOs)

  • Donald Hayden
    Chair, Board of Directors

    Don has held multiple board and senior executive positions. He has been President of Global Pharmaceuticals at Bristol-Myers Squibb and served as Board Chairman at REGENXBIO, Amicus Therapeutics, Insmed, Vitae Pharmaceuticals, Gloucester Pharmaceuticals, and WindMIL Therapeutics. He is Chairman of Otsuka America Pharmaceuticals Incorporated and Avanir Pharmaceuticals. His M.B.A. is from Indiana University and his B.A. from Harvard University.

  • Larry has expertise in biology, genetics, and neuroscience. He was a Full Professor at Harvard in Cell and Developmental Biology. He is currently a Professor Emeritus of Cellular and Molecular Medicine and Neuroscience at UC San Diego and Scientific Director of the Sanford Consortium for Regenerative Medicine. Larry co-founded Cytokinetics. He is a member of the American Academy of Arts and Sciences and the National Academy of Sciences.

  • Chief Business Officer

    Kim has over 20 years of biotechnology industry and Wall Street experience with expertise in capital markets, strategic corporate finance, corporate communications, and investor relations. Her prior experience includes Chief Corporate Affairs Officer at Taysha Gene Therapies. Kim received her B.S. from Stanford University and medical degree from Kirksville College of Osteopathic Medicine.

  • Chief Operating Officer

    Marcella is a seasoned life sciences executive with diverse successes within the corporate sphere and along the integrated drug development continuum. Previously, she was the Senior Vice President of Operations and Portfolio Management at Sumitovant Biopharma. Marcella serves as a Product Advisory Board member at Lokavant and an Adjunct Professor at Campbell University. Marcella has a BS, MBA and MS from the University of Wisconsin-Madison.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free